Canada markets closed
  • S&P/TSX

    19,290.98
    -19.76 (-0.10%)
     
  • S&P 500

    4,201.62
    +34.03 (+0.82%)
     
  • DOW

    34,548.53
    +318.19 (+0.93%)
     
  • CAD/USD

    0.8225
    +0.0072 (+0.88%)
     
  • CRUDE OIL

    64.94
    +0.23 (+0.36%)
     
  • BTC-CAD

    68,631.71
    -1,453.59 (-2.07%)
     
  • CMC Crypto 200

    1,468.60
    -2.81 (-0.19%)
     
  • GOLD FUTURES

    1,814.70
    -1.00 (-0.06%)
     
  • RUSSELL 2000

    2,241.42
    +0.05 (+0.00%)
     
  • 10-Yr Bond

    1.5610
    -0.0230 (-1.45%)
     
  • NASDAQ futures

    13,610.50
    +12.75 (+0.09%)
     
  • VOLATILITY

    18.39
    -0.76 (-3.97%)
     
  • FTSE

    7,076.17
    +36.87 (+0.52%)
     
  • NIKKEI 225

    29,331.37
    +518.77 (+1.80%)
     
  • CAD/EUR

    0.6815
    +0.0029 (+0.43%)
     

Seer to Report First Quarter Financial Results on May 10, 2021

  • Oops!
    Something went wrong.
    Please try again later.
Seer, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 10, 2021. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.

About Seer
Seer is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. Seer is developing its Proteograph™ Product Suite, which is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. Seer designed the Proteograph Product Suite to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that is broadly available to life sciences researchers. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio